Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2025 | YoY |
|---|---|---|
| Revenue | 910.3k | - |
| Gross profit | -14.81k | - |
| Net profit | -1.34m | - |
| EBITDA | -414.27k | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €11.9m |
Number of shares | 230.36m |
52-week high/low | €0.0594 - €0.0311 |
| Dividends | No |
Beta | 1.21 |
P/E ratio | 4.58 |
PEG ratio | 0.00 |
P/B ratio | 0.49 |
P/S ratio | 1.23 |
Company profile
AroCell AB (publ), a vitro diagnostics company, focuses on monitoring of hematological malignancies, breast cancer, and other solid tumors. The company develops, manufactures, and sells AroCell TK 210 ELISA, an immunoassay kit for the determination of Thymidine Kinase 1 in human blood. It also offers TUBEX TF, a bacteriological rapid test for diagnosis of typhoid fever. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was incorporated in 2000 and is based in Uppsala, Sweden.
| Name | AROCELL AB |
| CEO | Anders Hultman |
| Headquarters | Uppsala,
Sweden |
| Website | |
| Sector | Utilities |
| IPO | 28/07/2000 |
| Employees | 22 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Sto | AROC.ST |
Frankfurt | 80R.F |
Stockholm | AROC.ST |